U.S. markets close in 1 hour 47 minutes

Emisphere Technologies, Inc. (EMIS)

Other OTC - Other OTC Delayed Price. Currency in USD
Add to watchlist
7.02-0.04 (-0.57%)
As of 1:53PM EDT. Market open.
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close7.06
Open6.80
Bid0.00 x 0
Ask0.00 x 0
Day's Range6.80 - 7.07
52 Week Range3.88 - 9.16
Volume3,398
Avg. Volume25,346
Market Cap490.782M
Beta (5Y Monthly)1.36
PE Ratio (TTM)N/A
EPS (TTM)-0.10
Earnings DateAug 14, 2017 - Aug 18, 2017
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
N/A
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
View more
  • Is Emisphere Technologies (EMIS) a Smart Long-term Buy?
    Insider Monkey

    Is Emisphere Technologies (EMIS) a Smart Long-term Buy?

    Summers Value Partners recently released its Q3 2020 Investor Letter, a copy of which you can download here. The fund posted a return of -1.2% in the first nine months of 2020, outperforming its benchmark, the Russell 2000 Index which returned -9.6% in the same period. You should check out Summers Value Partners’ top 5 […]

  • GlobeNewswire

    EMISPHERE DEVELOPMENT UPDATE

    Novo Nordisk announced the European Commission (EC) has granted marketing authorization for Rybelsus®, (oral semaglutide), for the treatment of adults with insufficiently controlled type 2 diabetes to improve glycemic control as an adjunct to diet and exercise. The marketing authorization applies to all 27 European Union member states and the United Kingdom. Rybelsus® utilizes Emisphere Technologies, Inc.'s ("Emisphere" or the "Company") (EMIS) proprietary Eligen® SNAC Carrier Technology.